Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-09-21
2010-06-01
Shameem, Golam M. M. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S406000, C548S131000, C548S364700, C548S365100, C548S365700
Reexamination Certificate
active
07728018
ABSTRACT:
This invention concerns compounds of the general formula (1):and derivatives thereof, which are antagonists of 5-HT6receptors, wherein the symbols have the meanings given in the description. The invention also concerns methods for the preparation of these compounds, to novel intermediates useful for their synthesis, and to uses of such compounds and compositions, particularly their use in administering them to patients to achieve a therapeutic effect in treating at least on disease or condition chosen from Parkinson's disease, Huntington's chorea, schizophrenia, anxiety, depression, manic depression, psychoses, epilepsy, obsessive compulsive disorders, mood disorders, migraine, Alzheimer's disease, age related cognitive decline, mild cognitive impairment, sleep disorders, eating disorders, anorexia, bulimia, binge eating disorders, panic attacks, akathisia, attention deficit hyperactivity disorder, attention deficit disorder, withdrawal from abuse of cocaine, ethanol, nicotine or benzodiazepines, pain, disorders associated with spinal trauma or head injury, hydrocephalus, functional bowel disorder, Irritable Bowel Syndrome, obesity and type-2 diabetes.
REFERENCES:
patent: 2001/0053788 (2001-12-01), Lange
patent: WO 03/026647 (2003-04-01), None
patent: WO 03/026648 (2003-04-01), None
patent: WO 2007/020286 (2007-02-01), None
Antonio R. Damasio, Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, 20th edition (1996), vol. 2, pp. 1992-1996.
FDA mulls drug to slow late-stage Alzheimer's [online], [retrieved on Sep. 23, 2003]. Retrieved from the Internet, URL: http://www.cnn.com/2003/HEALTH/conditions/09/24/alzheimers.drug.ap/indez.html, pp. 1 and 2.
Molnar, “New drug policy in childhood obesity,” 2005, International Journal of Obesity, 29:S62-S65.
“Pain,” Merck Manuals Online Medical Library: Home Edition. Accessed Mar. 24, 2009. <http://www.merck.com/mmhe/sec06/ch078/ch078a.html>.
Stillman, Mark. “Clinical approach to patients with neuropathic pain.” Cleveland Clinic Journal of Medicine, 73 (8), pp. 726-730, 733-739.
Sv{hacek over (e)}tlik, J. et al., “Unexpected Ring Closure Reaction of [alpha], [beta]-Unsaturated Ketones with Aminoguanidine. Entry into 1,3,5-Trisubstituted Pyrazoles,”Journal of Heterocyclic Chemistry, U.S., vol. 39, No. 2, (2002), pp. 363-366, XP002468177.
Scott, F. L., et al., “Mechanism of Pyrazoline Formation from the Reactions of Substituted Hydrazines and Mannich Bases,”J. Chem. Soc. (C), 1971, pp. 80-86, XP009094752.
Database CHEMCATS [Online],Chemical Abstracts Service, Columbus, Ohio, US; (Apr. 7, 2004), XP002465985, Database accession No. 672331-19-0, compound of Registry No. 672331-19-0.
Database CAOLD [Online],Chemical Abstracts Service, Columbus, Ohio, US; (Jun. 11, 1988), XP002468179, Database accession No. 114794-17-1, compound of Registry No. 114794-17-1.
Database CHEMCATS [Online]Chemical Abstracts Service, Columbus, Ohio, US; (Sep. 2, 2003), XP002468180, Database accession No. 577791-34-5, compound of Registry No. 577791-34-5.
Scott, et al., “Nitrogen Systems. Part XIV1: The Synthesis of 1-Guanyl-Pyrazolines,”Chimia, Aarau, Ch, vol. 12, 1958, pp. 148-150, XP009094703.
Morales, M. et al., “Coexistence of Serotonin 3 (5-HT3) and CB1 Cannabinoid Receptors in Interneurons of Hippocampus and Dentate Gyrus,”Hippocampus, 2002, pp. 756-764, XP002468178.
International Search Report and Written Opinion, dated Mar. 3, 2008, issued in PCT/EP2007/059944.
Bentley et al., “Investigation of stretching behavior induced by the selective 5-HT6Receptor Ro 4-6790, in rats,”British Journal of Pharmacology(1999) 126, pp. 1537-1542.
Woolley et al, “A role for 5-ht6receptors in retention of spatial learning in the Morris water maze,”Neuropharmacology41 (2001) pp. 210-219.
Journal of Psychopharmacology, Supplement to vol. 11, No. 3, (1997) A64.
Bakker Wouter I. Iwema
Keizer Hiskias G.
Kruse Cornelis G.
Van Der Neut Martina A. W.
Van Loevezijn Arnold
Fierro Alicia L
Finnegan Henderson Farabow Garrett & Dunner
Shameem Golam M. M.
Solvay Pharmaceuticals B.V.
LandOfFree
Sulfonylpyrazole and sulfonylpyrazoline carboxamidine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfonylpyrazole and sulfonylpyrazoline carboxamidine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfonylpyrazole and sulfonylpyrazoline carboxamidine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4229023